United States radiological health activities: inspection results of mammography facilities
1 Division of Mammography Quality and Radiation
Programs, Food and Drug Administration, Rockville, Maryland, United States
2 SFA, Inc., Crofton, Maryland, United States
Purpose: The Mammography Quality Standards Act
(MQSA) was enacted in 1992 to set national standards for high-quality mammography,
including standards for mammographic X-ray equipment, patient dose, clinical
image quality, and related technical parameters. The MQSA also requires minimum
qualifications for radiologic technologists, interpreting physicians and
medical physicists, mandates acceptable practices for quality-control,
quality-assurance, and requires processes to audit medical outcomes. This paper
presents the findings of MQSA inspections of facilities, which characterize
significant factors affecting mammography quality in the United States.
Materials and Methods: Trained inspectors collected
data regarding X-ray technical factors, made exposure measurements for the
determination of mean glandular dose (MGD), evaluated image quality, and
inspected the quality of the film-processing environment. The average annual
facility and total U.S. screening exam workloads were computed using workload
data reported by facilities.
Results: Mammography facilities have made technical
improvements as evidenced by a narrower distribution of doses, higher
phantom-film background optical densities associated with higher phantom
image-quality scores, and better film processing. It is estimated that
approximately 36 million screening mammography exams were conducted in 2006, a
rate that is almost triple the exam volume estimated for 1997. Digital
mammography (DM) is now in use at approximately 14% (1,191 of 8,834) of
MQSA-certified mammography facilities. The results indicate that DM can offer
lower dose to the patient while providing comparable or better image quality. © 2007
Biomedical Imaging and Intervention Journal. All rights reserved.
The Mammography Quality Standards Act (MQSA) of 1992 was
enacted to set national standards for high-quality mammography and ensure that
clinical facilities in the U.S. meet those standards. In 1995, the Food and
Drug Administration (FDA) initiated a program of inspections of the then
approximately 10,000 mammography facilities to assess compliance with the MQSA
standards. Trained inspectors collected exposure and technique data to
determine radiation dose, evaluated phantom image quality, and tested the film
processing environment to ensure that clinical mammograms were developed
appropriately. The facility’s medical records were also evaluated for
compliance with quality control and quality assurance standards, appropriate
medical-audit processes, and for proper documentation of the professional
qualifications of interpreting physicians, radiologic technologists, and
medical physicists. Facilities that do not meet these standards must respond
with an acceptable corrective plan or face legal action.
The specific MQSA technical standards for X-ray equipment,
patient dose, and image quality were motivated in part by studies between the
1970s and the early 1990s [1,2] that documented the broad range of technical
performance by mammography facilities. For example, although mammography
quality had improved substantially as a result of better equipment performance
through dedicated screen and film combinations, improved film processing, and
the use of grids, other technical parameters- dose, background film optical
density, and image quality indicators- still showed a broad range of values.
The American College of Radiology (ACR) had initiated an accreditation program
for mammography, and facilities could also be accredited through their state or
become certified with the Health Care Financing Administration (HCFA). However
in 1992, 23% of mammography facilities carried no credentials from a recognised
professional organisation . A subsequent study by Suleiman  et al. in
1999 documented improvements after three years of MQSA inspections for most
areas of technical performance. This report discusses further trends in the
practice of mammography after 11 years of MQSA inspections, and it focuses on
technical indicators of quality and trends in the rate at which the U.S. population is screened for breast cancer.
Prior to the early 2000s mammography in the U.S. was based essentially on screen-film (SF) technology. Digital mammography (DM) was
first approved for clinical use in the U.S. in 2000 and is now offered in 14%
of MQSA-certified facilities. It has unique technical advantages over
conventional screen-film technology by separating the technology for capturing
images from the media for viewing and storing them. A disadvantage, however, is
that unlike film, whose inherently limited sensitometric range of exposure acts
to constrain the dose to the patient, DM equipment is capable of producing
images of acceptable quality for a broad range of doses . Nevertheless,
studies [5,6] indicate the potential for DM to offer a lower dose than SF
technology, and the extensive ACR Imaging Network-Digital Mammographic Imaging
Screening Trial (ACRIN-DMIST) study comparing DM and SF concluded that DM is
clinically superior for patients under the age of 50 years, premenopausal or
perimenopausal patients, and patients with radiographically dense breasts, but
is otherwise comparable in overall diagnostic accuracy for screening for breast
cancer . This paper also compares inspection findings for DM with those of
conventional SF imaging and discusses the impact of DM on general practice.
Finally, although some studies question the benefit of
population-wide mammography screening , it is generally accepted that there
is benefit to the patient over and above the radiation and other risks involved
[9,10,11]. This paper also examines facility annual screening workloads and
provides estimates for total annual exam volumes in the U.S.
Equipment and Procedures
Each MQSA-certified inspector is required to pass a series
of three training courses provided by the FDA and complete additional field
testing prior to conducting MQSA inspections independently. Each inspector was
provided all the necessary equipment to make radiation dosimetry measurements,
evaluate image quality and film processing quality, and inspect the processing
darkroom environment. Exposure measurements for the determination of beam
quality and mean glandular dose (MGD) were made with the MDH model 1015 (Radcal
Corporation, Monrovia, CA) survey meter equipped with the 10X5-6M mammography
ionisation chamber. The radiation meter and ionisation chamber were calibrated
annually by the FDA’s X-ray calibration facility, which is accredited by the
National Voluntary Laboratory Accreditation Program (NVLAP). Exposure
measurements were done with a standard mammography phantom having radiographic
attenuation properties equivalent to that of a 4.2-cm compressed breast composed
of 50% glandular and 50% adipose tissue. Beam quality (half-value layer) was
determined for the clinically configured kVp using type 1145 aluminum. MGD in
this standard breast model was then computed using conversion factors derived
by Wu, Barnes and Tucker . The phantom also contains three sets of
image-quality test objects: fibril-like objects, speck groups that simulate
micro-calcifications, and mass-like objects, and it is commercially available
(model 156 mammography accreditation phantom, Gammex RMI, Inc., Middleton, WI).
A radiograph of the phantom was acquired using the same technical factors as
those used for dosimetry data collection, and it was then evaluated for
appropriate background optical density and acceptable image quality. MQSA requirements
for phantom film image quality include a minimum background optical density of
1.2 and minimum scores for the three groups of test objects (including artefact
subtraction): four fibers out of a possible score of six, three speck groups
out of a possible five groups, and three masses out of a possible score of
five. If a phantom radiograph failed for one or more of the test objects, a
second radiograph was scored to confirm the assessment prior to citing the
facility as non-compliant. After May 2006, MQSA inspectors no longer measured
mammographic phantom doses themselves but instead captured dose values
documented in the reports of the required annual medical physics surveys.
During the transition away from independent dose measurements by MQSA inspectors,
the FDA conducted a comparison study and validated (p < 0.001) the
equivalence of the two means of assessing the dose in the standard breast.
Film processing quality was evaluated using the
Sensitometric Technique for the Evaluation of Processing (STEP) [3,13]. A
reference automatic film processor was configured for processing a selected
test film according to the specifications recommended by the film manufacturer.
The same film type was then distributed to all MQSA inspectors along with
sensitometers calibrated to an FDA reference sensitometer, and densitometers
that were calibrated to the National Institute of Standards and Technology
(NIST) reference standard densitometry step tablet (SRM 1001). A relative speed
value was determined for the facility’s film processor based on a comparison of
optical densities from the test film processed at the facility versus the same
film when processed in the FDA reference film processor. A processing speed of
100 was assigned if the tested film processor was operating in close agreement
with film manufacturer specifications, whereas speeds greater than 120 or less
than 80 (for standard cycle processing) indicate substantial deviation from
acceptable film-processing levels. A film processing speed below 80 indicates
substantial under-processing of the film and a facility could be motivated to
compensate by increasing exposure. For this reason, MQSA regulations require a
minimum film processor speed of 80. Extended cycle processing, where the film
is developed over a longer period of time (a total development time of
approximately 3 minutes as opposed to 90 seconds typically for standard cycle),
results in a STEP processing speed of approximately 130 or greater depending on
the processor and the film brand and type. MQSA requires extended cycle film
processors to have a minimum processing speed of 100. MQSA has not specified a
maximum permissible film processor speed for either processing cycle.
An undeveloped radiograph of the phantom was used to
evaluate the darkroom environment for sources of radiographic fog. The film was
placed in an area of the darkroom where mammography film is routinely handled,
and then it was bisected so that approximately half of the latent image of the
phantom was exposed to ambient darkroom conditions for 2 minutes. The film was
then developed and inspected for an increase in the background optical density.
If a distinct area of higher optical density was observed on the exposed side
of the border, then the inspector determined the net increase in optical
density across the border. MQSA requires that facilities maintain darkroom fog
levels of net optical density not greater than 0.05.
MQSA-certified clinical facilities began reporting annual
screening mammography workloads in 1997. Facilities were asked to provide
annual workload rates during their initial application for mammography
accreditation and during subsequent certification renewal. Average facility and
total U.S. screening workloads were then derived using figures for the total number
of certified mammography facilities. It was assumed that the workload sample
set reported to FDA for each year, ranging from 7% to nearly 30% of all
certified facilities, is representative of the U.S. state of practice.
Between 1997 and 2006, the total number of screening
mammography exams performed annually in the U.S. increased linearly (r2=0.91)
from approximately 13.8 ± 1.6 (mean ± standard error) million exams to 35.8 ±
1.9 million exams (Figure 1). Figure 1 also displays the contribution to the
total U.S. screening workload for specific facility types: hospitals, private
practice facilities such as outpatient radiology facilities, dedicated breast
clinics, and facilities that were classified as ‘other’ if they did not meet
the criteria for the preceding three facility categories. The calculations do
not account for additional contributions from a small number (approximately 30)
of the Department of Veterans Affairs facilities that may perform mammography
but are not required to be compliant with MQSA regulations. Hospitals and
private practices, which from 1995 to 2006 constituted approximately 42% and
48% of all certified mammography facilities respectively, consistently
contributed the majority (over 80 percent) of screening exams. Dedicated breast
clinics, which account for less than 6% of all mammography facilities, were
found to consistently have the highest average facility screening exam workload
of all identifiable facility types (excluding ‘other’) (Figure 2). All types of
facilities increased their number of mammography units (Figure 3), which is
consistent with the observation that while the number of certified mammography
facilities has actually decreased since 1995 from approximately 10,000
facilities to just over 8,800 facilities, the total number of exams in the U.S.
has increased substantially.
Dose and Image Quality
Tables 1 and 2 summarize statistics for selected technical
aspects of mammography in the U.S. for 1995 and 2006. During this time period
there was a statistically significant increase in average MGD (p < 0.001)
from 1.51 mGy to 1.78 mGy (Tables 1 and 2). The distribution of doses (Figure
4) about the mean decreased during the same time period, and this trend was
observed across every type of facility. Dose is partly determined by the
selected tube potential (kVp), and although the mean clinically selected tube
voltage (kVp) did not change appreciably between 1995 and 2006, the
distribution has narrowed (Figure 5). Over 90% (7,865 of 8,586) of inspected
mammography units are now using either 25 or 26 kV, whereas in 1995 over 25%
(3,068 of 11,697) of inspected units were operated at 27 kV or higher. The
standard deviation for kVp decreased by almost half for every type of facility
except breast clinics, which had the narrowest distribution in 1995. Half-value
layer (HVL) followed a trend similar to that for kVp. The mean for HVL changed
very little across all types of facility since 1995, but private practice sites
had a standard deviation for HVL in 2006 that was less than half of the
standard deviation for 1995.
Although a higher dose translates to higher radiation risk
for the patient, MQSA data also demonstrated an increase in benefit as
indicated by improved image quality performance. Phantom image background
optical density increased substantially from a mean optical density of 1.42 in
1995 to 1.85 in 2006. This finding indicates that film contrast performance
should improve because most mammography films currently in use provide optimal
image contrast at optical densities approaching 2.0 . Indeed, although
there was improvement in all three object groups (Tables 1 and 2), the fibre
and mass groups showed the most statistically significant improvement between
1995 and 2006, the visualisations of which are dependent on the contrast
performance of the film and therefore sensitive to the background optical
density . MQSA requires mammography facilities to maintain a phantom image
background optical density of at least 1.2.
Artefacts are a detriment to the clinical value of the
mammogram and can arise from many sources including contaminated film
cassettes, the film processor, the darkroom environment, improper film
handling, and the mammography unit compression paddle, among other sources .
Between 1995 and 2006, there was a 10% increase in the incidence of artefacts
reported on phantom image films scored by MQSA inspectors from 60% (6,979 of
11,676) of inspected mammography units in 1995 to 70% (6,502 of 9,307) of
inspected mammography units. Across all types of facilities, speck-like
artefacts were the most frequent type reported, occurring on 58% (6,745 of
11,676) of mammography units inspected in 1995 and on 68% (6,293 of 9,307) of
mammography units inspected in 2006. Mass-like artefacts were the least frequently
reported artefact type, and occurred on less than 5% of mammography units 1995
(523 of 11,676) and 2006 (323 of 9,307). Improvements in film processing
technology, maintenance of mammography equipment, and adherence to acceptable
quality control and quality assurance practices can reduce artefacts. However,
if film contrast performance improves as indicated by higher background optical
densities, then the visualisation of artefacts may also improve. Finally, the
training and experience of inspectors can influence the reporting of artefacts.
Film processing and darkroom fog
Reports have documented substantial improvements in film
processing quality by mammography facilities between 1985 and 1997 [2,3].
During this period, extended cycle processing was used by a substantial number
of facilities. In 1992, 26% of surveyed facilities claimed to use extended
cycle processing, and three quarters of these sites had sub-optimal processing
quality for this particular processing cycle . The rate of film processors
that facilities claimed to operate in extended cycle mode reached 43% (2,743 of
6,459) in 1995, but by 2006 extended cycle processing nearly vanished. Nearly
97% (5,861 of 6,068) of film processors are presently being operated in a
standard cycle mode. Regardless of the processing cycle, MQSA inspection
results document that mammography facilities have maintained high quality in
film processing. During the first year of inspections 4% (243 of 6,459) of
tested film processors (all processor cycles) were found to have a STEP
processing speed below the MQSA action limit, and by 2006 this percentage
dropped to near zero (3 of 6,068). The high rate of compliance with the MQSA
standard for film processing can be attributed to better quality control and
quality assurance practices, improvements in film and chemical processing
technologies, and a heightened awareness by facilities and the professional
community regarding the impact that film processing quality can have on
clinical image quality. Whereas film processor control charting merely tracks
the drifting of processing quality from a pre-established and possibly
arbitrary operating level, the STEP film processor test can provide a benchmark
operating point for film processing of optimal quality.
Reducing radiographic film fog in the darkroom to
acceptable levels is a simple yet often ignored aspect of quality control. In
1992, 62% of clinical facilities had darkroom fog levels in excess of the
current MQSA standard (net optical density no greater than 0.05) . During
the first year of MQSA inspections, 11% (778 of 7,030) of inspected darkrooms
exceeded this limit, and by 2006, the non-compliance rate dropped to less than
5% (233 of 5,587), with breast clinics showing the highest rate of compliance
Table 2 includes findings of selected parameters for DM
and SF units inspected between January and September 2006. DM was first
approved in the U.S. in 2000, and currently there are approximately 1,689 DM
units in use at 1,191 certified mammography facilities (Figure 6), comprising
approximately 14% of the total population of certified mammography facilities.
Figure 7 shows a geographical distribution of DM sites and SF sites. Because of
the complexities regarding the evaluation of dose and quality assurance/quality
control procedures that tended to be specific to each manufacturer, the FDA
conducted abbreviated inspections of digital facilities to verify that the
manufacturers’ recommended practices were being instituted. MGD was captured from
the medical physics survey report, and image quality was evaluated by the FDA
inspector using the same standard phantom as that used for screen-film
mammography. Data analysis of DM was conducted on inspections that took place
between August 2005 and October 2006 in order to include all inspected digital
The distribution of digital equipment across the different
types of facilities is similar to that for screen-film equipment (Figure 8).
The majority of digital sites are hospitals; however breast clinics comprise
11% (72 of 633) of digital sites compared with 6% (345 of 6,010) of screen-film
sites. Facilities using DM reported an average facility annual workload (6,938
exams per year, N=75), approximately double the average for SF sites (3,524
exams per year, N=1212) (Figures 9).
Dose and Image Quality
Figures 10 and 11 display distributions of MGD and phantom
image quality score for facilities using SF and DM. The average MGD for DM
units (1.63 mGy) was statistically lower (p < 0.001) than that for SF units
(1.80 mGy). Both means are well below the MQSA compliance limit for MGD of 3.0
mGy for a single (craniocaudal) view. The standard deviations for MGD in Table
2 and the dose distributions in Figure 10 highlight the broader range of doses
for DM. MQSA inspectors did not collect any dose-related technical factors such
as clinically selected kVp, beam quality, or target-filter selection during the
inspection of DM units, and therefore it is not possible to compare these
parameters between the two technologies.
inspector imaged the phantom on the DM unit and scored the image using the same
format (hard-copy or soft-copy workstation) as that routinely used by the
facility. Sixty-two percent (554 of 889) of DM phantom images were scored
on a computer monitor. If the soft-copy image score failed to meet minimum
standards, a hard-copy image was evaluated prior to issuing a citation to the
facility. Table 2 summarises image quality scores for the three individual
object groups (without artefact subtraction), and the total net score,
including artefact subtraction. Average image quality score (net score
including artefact subtraction) for DM (13.5 objects) was significantly higher
(p < 0.001) than for SF (12.3 objects). If the presence of artefacts is not
accounted for, the difference between the mean raw total score for SF (12.8
objects) and DM (13.6 objects) decreased (Figure 11), but was still
statistically significant (p < 0.001). Most of the contribution to higher
total raw scores for DM was from the mass object group (p < 0.001), while
the smallest yet also statistically significant (p < 0.001) difference was
observed for the speck object group.
Analysis of raw object scores can indicate the overall
ability of the system to visualize clinically relevant features, whereas the
presence of image artefacts is an indicator of the tendency of the system to
superimpose false structures on the clinical image. Seventy-three percent
(6,270 of 8,568) of phantom images produced using SF technology were found to
have at least one artefact compared to 30 percent (267 of 892) of phantom
images produced using DM. For both modalities, the artefact type that was
identified most frequently by the inspector was a speck-like artefact, and
occurred in 25% (222 of 892) of DM images and 71% (6,102 of 8,568) of SF
images. The least frequent artefact type was a mass-like artefact, identified
on only 2% (17 of 892) of DM images and 4% (306 of 8,568) of SF images. Specifically for DM, there was a
slightly higher occurrence of artefacts for soft-copy review than for the
hard-copy format across all object groups, and overall artefacts were observed
on 24% (82 of 335) of hard-copy films and on 33% (183 of 554) of soft-copy
images. Possible reasons for the much lower incidence of artefacts with DM
compared to SF may include the elimination of conventional film processing and
related artefacts associated with SF, and any software-based image processing
features or other electronic features in DM such as flat-field corrections that
may reduce the presence or visualisation of artefacts.
Is better image quality associated with higher dose? In
screen-film imaging, reducing dose can result in lower image quality scores
depending on the sensitometric properties of the film. In DM, the pixel-based
signal-noise ratio can be reduced. For both SF and DM, linear regression
analysis for a dependence of phantom image quality score (without artefact
subtraction) on dose yielded only a weak relationship (correlation coefficient
(r) < < 1). However, the null hypothesis- that the slope of the
regression line is zero- was rejected (p < 0.001) for both imaging
modalities. Testing was also performed for a possible difference in image
quality between mammography units that produced doses below 1.0 mGy compared
with mammography units having doses greater than 2.0 mGy. These ranges were
selected because they exclude the average dose values that have occurred for
the populations of inspected facilities between 1995 and 2006. For SF
mammography, the average raw total score for doses below 1.0 mGy was 12.3
objects compared with 13.0 objects for doses greater than 2.0 mGy. For DM, the
corresponding average image quality scores were 13.1 and 13.8 objects,
respectively, for doses below 1.0 mGy and above 2.0 mGy. The difference in
average raw total score for the two dose groups is statistically significant (p
< 0.001) for both SF and DM. These findings, which characterize aspects of
the dose-phantom image quality relationship for a population that is representative
of the state of practice, demonstrate that dose has a weak but observable
impact on image quality (Figure 12). Haus et al.  observed a similar
relationship in which phantom image score failure rates were significantly
higher for doses below 1.0 mGy compared with doses in the range of 1.5-2.0 mGy.
Discussion and Conclusions
The annual number of screening mammography exams conducted
in the U.S. has steadily increased between 1997 and 2006, with hospitals and
private practice sites conducting the majority of exams. DM is allowing
facilities to increase their exam workloads, and such facilities are estimated
to conduct almost a quarter of all mammography exams.
Screen-film based mammography in the U.S. has matured
technically as both imaging equipment performance and facility clinical
practices have promoted reduced variability in MGD and indicators of image
quality. Figure 13 shows the trends in mammography dose and image quality in
the U.S. between the mid-1970s and 2006, and it highlights two aspects of the
clinical practice. Prior to the 1990s, changes in the technical aspects of
mammography dramatically reduced radiation dose (risk) and improved image
quality (clinical benefit). As mammography technology matured and mandatory
quality standards were instituted nationally, dose actually increased slightly
as the professional community optimised image quality to a stable level.
Average MGD in the U.S. currently is higher than those
reported in surveys conducted in several other countries. Young et al. reported
for the UK in 2001 and 2002 an average MGD of 1.42 mGy for a slightly larger
compressed breast thickness of 45 mm in their model . They also reported a
similar increasing trend in dose in the breast model compared to a previous
survey conducted there in 1997 to 1998. A survey conducted in the Netherlands
also reported lower doses; however breast doses were based on tissue
glandularity and an average compression thickness between 5.4 cm (average MGD
of 1.04 mGy) and 6.2 cm (average MGD of 1.63 mGy) depending on locality .
Jamal et al. reported an average MGD from a survey in Malaysia conducted
between 1999 and 2001 of 1.23 mGy using the RMI model 156 phantom  and
reported an average phantom image background optical density (1.28) well below
the value reported in this paper for the U.S. in 2006. Image quality indicators
should be considered before concluding that there is a clinical benefit to
administering lower doses.
Film processing quality in the U.S. has continued to improve and
standard cycle processing has become the de facto standard in mammography. In
1995, over 25% (957 of 3,717) of tested (standard cycle) film processors were
operating at a speed below 90 compared with only 1.3% (73 of 5,861) of film
processors tested in 2006. This observation and the fact that dose has actually
increased on average both indicate that facilities have increasingly directed
their efforts toward improving clinical benefit.
Although screen-film based mammography is still the
dominant imaging format, data reported in this paper suggest that DM can offer
at least comparable and possibly superior image quality performance with lower
mammographic dose. This study did not evaluate additional features provided by
digital-based imaging such as computer-assisted manipulation of the image.
Although these findings suggest that DM is currently producing better image
quality as indicated by higher scores for test objects including significantly
fewer artefacts, it remains to be shown that they are clinically significant. The
results of the ACRIN DMIST trial  indicating that DM is not superior to SF
imaging for all patients is consistent with the conclusion that DM at this time
is still a maturing technology not yet definitively superior to screen-film
Figure 1 Total U.S. screening mammography annual examination workload, and contributions by facility type. Standard errors for the total annual estimates ranged between 3% and 12%.
Figure 10 Mean glandular dose for screen-film versus digital mammography units. For both modalities dose was captured from the facility’s medical physics survey report. Box bottom and top borders are 25th and 75th percentiles respectively, and box contents are 50th percentile (line) and mean value (diamond). Whiskers indicate 5th and 95th percentiles.
Figure 11 Phantom image-quality score for screen-film versus digital mammography units. Total score without artifact subtraction is reported. Box bottom and top borders are 25th and 75th percentiles respectively, and box contents are 50th percentile (line) and mean value (diamond). Whiskers indicate 5th and 95th percentiles.
Figure 12 Scatter plots and linear fits of mean phantom image score (without artifact subtraction) versus mean glandular dose. Note that phantom scores are constrained to integer and half-integer values.
Figure 13 Dose and image quality trends in the United States. Data were obtained from the following sources. 1974 (dose): Bicehouse HJ. Survey of Mammographic Exposure Levels and Techniques Used in Eastern Pennsylvania. 7th Annual National Conference on Radiation Control, 1975. DHEW Publication (FDA) 76-8026. 1976 (dose): Butler PF, Jensen JE. Breast Exposure: Nationwide Trends; A Mammographic Quality Assurance Program- Results to Date. Radiologic Technology 50(3), 1978; pp 251-257. 1980 (dose): Breast Exposure: Nationwide Trends. In: Internal project progress report. Rockville MD: Bureau of Radiological Health, US Department of Health and Human Services, Food and Drug Administration, 1981. 1985, 1988, 1992 (dose and image quality): Conway BJ, Suleiman OH, Rueter FG, Antonsen RG, Slayton RJ. National Survey of Mammographic Facilities in 1985, 1988, and 1992. Radiology 1994; 191: 323-330. 1995-2006 (dose and image quality): Mammography Quality Standards Act (MQSA) inspection findings. Image Quality scores are reported for following phantoms: 1985: RMI 152 phantom with 'C' insert; 1988: RMI 156 phantom with 'C' insert; 1992 to present: RMI 156 phantom with 'D' insert (or equivalent)
Figure 2 Box-whisker plots of facility screening mammography workloads reported between January 2006 and October 2006. Box bottom and top borders are 25th and 75th percentiles respectively, and box contents are 50th percentile (line) and mean value (diamond). Whiskers indicate 5th and 95th percentiles.
Figure 3 Distributions for 1995 (left) and 2006 (right) of the number of mammography units per facility used for mammography examinations by facility type.
Figure 4 Box-whisker plots of mean glandular dose from MQSA inspections conducted in 1995 and 2006. Dose values for 1995 are those determined by the MQSA inspector. Values for 2006 are those reported in the facility medical physics survey report. Box bottom and top borders are 25th and 75th percentiles respectively, and box contents are 50th percentile (line) and mean value (diamond). Whiskers indicate 5th and 95th percentiles.
Figure 5 Distributions of mammography unit clinically selected tube potential (kVp) for 1995 and 2006 MQSA inspections.
Figure 6 Number of accredited digital mammography (DM) units (circles) and the number of certified mammography facilities they reside in (squares).
Figure 7 Geographic distribution of screen-film and digital facilities in the U.S. for 2005-2006. A facility was classified as a digital site if it had at least one digital mammography unit. A facility that has digital mammography may also have conventional screen-film technology, and therefore was included in the latter category as well.
Figure 8 Distributions of facility types for mammography facilities using only screen-film technology (left) and for facilities that had at least one digital mammography unit (right). Data for screen-film is for January to October, 2006. Data for digital mammography is from August 2005 to October 2006.
Figure 9 Annual screening exam workload per facility for sites that used only screen-film technology and for sites that had at least one digital mammography unit. Box bottom and top borders are 25th and 75th percentiles respectively, and box contents are 50th percentile (line) and mean value (diamond). Whiskers indicate 5th and 95th percentiles.
Table 1 MQSA inspection results for selected technical parameters: January to December, 1995.
Table 2 MQSA inspection results for selected technical parameters: January to September 2006.
Jans RG, Butler PF, McCrohan JL Jr et al. The status of film/screen mammography. Results of the BENT study. Radiology 1979; 132(1):197-200.
Conway BJ, Suleiman OH, Rueter FG et al. National survey of mammographic facilities in 1985, 1988, and 1992. Radiology 1994; 191(2):323-30.
Suleiman OH, Spelic DC, McCrohan JL et al. Mammography in the 1990s: the United States and Canada. Radiology 1999; 210(2):345-51.
Equipment. in: National Council of Radiation and Measurements. A Guide to Mammography and Other Breast Imaging Procedures. 2004. (NCRP Report; 149).
Gennaro G, di Maggio C. Dose comparison between screen/film and full-field digital mammography. Eur Radiol 2006; 16(11):2559-66.
Berns EA, Hendrick RE, Cutter GR. Performance comparison of full-field digital mammography to screen-film mammography in clinical practice. Med Phys 2002; 29(5):830-4.
Pisano ED, Gatsonis C, Hendrick E et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005; 353(17):1773-83.
Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355:129-34.
Feig SA. Adverse effects of screening mammography. Radiol Clin North Am 2004; 42(5):807-19, v.
United States Department of Health and Human Services. [Press Release]. 2002.
Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353(17):1784-92.
Wu X, Barnes GT, Tucker DM. Spectral dependence of glandular tissue dose in screen-film mammography. Radiology 1991; 179(1):143-8.
Suleiman OH, Rueter FG, Antonsen RG et al. The sensitometric technique for the evaluation of processing (STEP). Radiat Prot Dosimetry 1993; 49:105-6.
West MS, Spelic DC. Using light sensitometry to evaluate mammography film performance. Med Phys 2000; 27(5):854-60.
Haus AG, Yaffe MJ, Feig SA et al. Relationship between phantom failure rates and radiation dose in mammography accreditation. Med Phys 2001; 28(11):2297-301.
The American College of Radiology. Mammography Quality Control Manual. American College of Radiology, 1999.
Young KC, Burch A, Oduko JM. Radiation doses received in the UK Breast Screening Programme in 2001 and 2002. Br J Radiol 2005; 78(927):207-18.
Zoetelief J, Veldkamp WJ, Thijssen MA et al. Glandularity and mean glandular dose determined for individual women at four regional breast cancer screening units in the Netherlands. Phys Med Biol 2006; 51(7):1807-17.
Jamal N, Ng KH, McLean D. A study of mean glandular dose during diagnostic mammography in Malaysia and some of the factors affecting it. Br J Radiol 2003; 76(904):238-45.
Toledano A, Pisano E, Yaffe M et al. Relationship of Diagnostic Accuracies of Film-Screen and Digital Mammography to Breast Density in the DMIST Conducted by the American College of Radiology Imaging Network (ACRIN). in: Breast Imaging (Digital Mammography: The ACRIN DMIST Results). SSA15. (92nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).
|Received 22 December 2006; accepted 2 January 2007
Correspondence: Division of Mammography Quality and Radiation Programs, Food and Drug Administration, 1350, Piccard Drive HFZ-240, Rockville, MD 20850, United States. Tel.: +240-276-3312; Fax: +240-276-3272; E-mail: email@example.com (David Spelic).
Please cite as: Spelic DC, Kaczmarek RV, Hilohi M, Belella S,
United States radiological health activities: inspection results of mammography facilities, Biomed Imaging Interv J 2007; 3(2):e35
This article has been viewed 6851 times.